Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

AngioSoma, Inc. Enters Discussions with Nutraceutical Intellectual Property Owners

AngioSoma,Inc.
Posted on: 22 Sep 16

AngioSoma, Inc. (the 'Company', 'we', and 'our') (OTCQB: SOAN), announces the formation of the Soma Nutraceuticals, Inc. subsidiary for the acquisition and marketing of proven nutraceutical products, as well as acquisition discussions with multiple proven nutraceutical intellectual properties. Our Chairman Emeritus “Doc” Summers owns some of the proven nutraceutical products we are reviewing for acquisition. The Company is recruiting subsidiary management which have a mass marketing nutraceutical product focus.

If we could introduce my Stemulite™ products to the market again, I believe that we could achieve the revenue throughput that Endothil achieved at $10,000,000+ per year in 2008,” said Chairman Emeritus David “Doc” Summers.

AngioSoma, Inc. also updated its website at http://angiosoma.com and its Twitter feed at https://twitter.com/angiosoma_admin.

ABOUT ANGIOSOMA, INC.

AngioSoma, Inc. (http://angiosoma.com) is a clinical stage biopharmaceutical company focused on improving the effectiveness of current standard-of-care treatments, especially related to endovascular interventions in the treatment of peripheral artery disease ('PAD'). Our lead pharmaceutical product Liprostin™, a treatment for PAD, has successfully completed FDA Phase I and three Phase II clinical trials, and we are in discussions with several contract research organizations for rapid completion of our U.S. Food and Drug Administration ('FDA') approved protocol for Phase III with submission of our new drug application for marketing in the U.S. and its territories.

NOTICE REGARDING FORWARD LOOKING STATEMENTS

This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements that include the words “believes,” “expects,” “anticipate” or similar expressions. Such forward-looking statements involve known and unknown risks, and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone’s past success is no guarantee of future success. This news release speaks as of the date first set forth above and the company assumes no responsibility to update the information included herein for events occurring after the date hereof.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160922005175/en/

Business Wire
www.businesswire.com

Last updated on: 22/09/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.